Skip to main content

Table 1 Efficacy trials of acellular pertussis vaccine [10, 64, 65]

From: The Pertussis resurgence: putting together the pieces of the puzzle

Study year Study location/name Design and methods Number of participants Comments.
1985 [18] Sweden, Stockholm Double blind placebo controlled (compared two Japanese aP vaccines) 3801 No wP control group.
2 dose schedule
1991 [66] Sweden
GÖteborg
Double blind placebo controlled (compared DT/DTP) 3450 No wP control
3 dose schedule.
1992 [67] Germany, Mainz Passive monitoring of household contacts 360 contacts 3 dose schedule
1992 [68] Sweden, Stockholm Double blind placebo controlled (two-compenent aP/five component aP/wP/DT) 24,336 wP control – (Conaught)
3 dose schedule
1992 [69] Italy Double blind placebo controlled
(aP/wP/DT)
14,751 wP control – (Conaught)
3 dose schedule
1993 [70] Germany, Munich Case control study
(aP/wP/DT/no vaccine)
16780 3 dose schedule
1990 [71] Senegal -Double blind placebo controlled
-Household contact (aP/wP)
4181 No placebo control
3 dose schedule
Late 90′s [72] Germany, Erlangen Prospective study,
2 groups randomized to aP or wP, third group (not randomized) received DT.
  4 dose schedule